Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.31 |
| ▸ | TPH1 | P17752 | 2/20 | 0.31 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.31 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19687203 | 0.87 | IDH1 (0.34) | IDH1TPH1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL21144176 | 0.83 | HTT (0.45) | — | |
| SCHEMBL21144188 | 0.81 | IDH1 (0.33) | IDH1 | |
| SCHEMBL21143874 | 0.80 | IDH1 (0.34) | IDH1OPRM1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL21143623 | 0.80 | IDH1 (0.30) | IDH1 | |
| SCHEMBL21143593 | 0.80 | IDH1 (0.30) | IDH1 | |
| SCHEMBL21144111 | 0.74 | IDH1 (0.39) | IDH1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL19686534 | 0.73 | IDH1 (0.48) | IDH1 | |
| SCHEMBL19687472 | 0.71 | HTT (0.41) | — | |
| SCHEMBL20153240 | 0.71 | NAPEPLD (0.33) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885AVPR2 722/4885AVPR1A 901/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885AVPR2 722/4885AVPR1A 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.